iNOVA Pharmaceuticals has
secured the rights to bring a new
therapy option for the treatment of
chronic obstructive pulmonary
disease to Australia, Erdosteine.
The drug works by improving the
rheological (flow) properties of the
sputum and reducing sputum volume.
The manufacturer also says the
product is also thought to reduce
bacterial adhesiveness and to have
anti-inflammatory and anti-oxidant
properties.
Although not yet approved for use
in Australia by the TGA, iNova
representatives are confident of the
drug gaining Australian marketing
approval, following its approval in
Europe, South America and Asia.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Oct 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Oct 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.